Chien Wei-Wen, Le Beux Céline, Rachinel Nicolas, Julien Michel, Lacroix Claire-Emmanuelle, Allas Soraya, Sahakian Pierre, Cornut-Thibaut Aurélie, Lionnard Loïc, Kucharczak Jérôme, Aouacheria Abdel, Abribat Thierry, Salles Gilles
Université Claude Bernard Lyon 1, UMR 5239 CNRS ENS HCL, Faculté de Médecine Lyon Sud, 165 Chemin du Grand Revoyet, 69921, BP12, Oullins, FRANCE.
Alizeé Pharma, 15 Chemin du Saquin, Espace Européen, Building G, 69130, Ecully, FRANCE.
Sci Rep. 2015 Jan 28;5:8068. doi: 10.1038/srep08068.
Bacterial L-asparaginase (ASNase), hydrolyzing L-asparagine (Asn), is an important drug for treating patients with acute lymphoblastic leukaemia (ALL) and natural killer (NK) cell lymphoma. Although different native or pegylated ASNase-based chemotherapy are efficient, disease relapse is frequently observed, especially in adult patients. The neo-synthesis of Asn by asparagine synthetase (AsnS) following ASNase treatment, which involves the amino acid response and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways, is believed to be the basis of ASNase-resistance mechanisms. However, AsnS expression has not emerged as an accurate predictive factor for ASNase susceptibility. The aim of this study was to identify possible ASNase sensitivity/resistance-related genes or pathways using a new asparaginase, namely a pegylated r-crisantaspase, with a focus on classic Asn-compensatory responses and cell death under conditions of Asn/L-glutamine limitation. We show that, for B-ALL cell lines, changes in the expression of apoptosis-regulatory genes (especially NFκB-related genes) are associated with ASNase susceptibility. The response of malignant NK cell lines to ASNase may depend on Asn-compensatory mechanisms and other cellular processes such as cleavage of BCL2A1, a prosurvival member of the Bcl-2 protein family. These results suggest that according to cellular context, factors other than AsnS can influence ASNase susceptibility.
细菌L-天冬酰胺酶(ASNase)可水解L-天冬酰胺(Asn),是治疗急性淋巴细胞白血病(ALL)和自然杀伤(NK)细胞淋巴瘤患者的重要药物。尽管不同的天然或聚乙二醇化的基于ASNase的化疗方法有效,但疾病复发仍经常出现,尤其是在成年患者中。ASNase治疗后,天冬酰胺合成酶(AsnS)重新合成Asn,这涉及氨基酸反应和丝裂原活化蛋白激酶激酶/细胞外信号调节激酶途径,被认为是ASNase耐药机制的基础。然而,AsnS表达尚未成为ASNase敏感性的准确预测因子。本研究的目的是使用一种新的天冬酰胺酶,即聚乙二醇化的r-克瑞杉天冬酰胺酶,确定可能与ASNase敏感性/耐药性相关的基因或途径,重点关注在Asn/L-谷氨酰胺限制条件下的经典Asn补偿反应和细胞死亡。我们发现,对于B-ALL细胞系,凋亡调节基因(尤其是NFκB相关基因)表达的变化与ASNase敏感性相关。恶性NK细胞系对ASNase的反应可能取决于Asn补偿机制和其他细胞过程,如Bcl-2蛋白家族的促生存成员BCL2A1的裂解。这些结果表明,根据细胞环境,除AsnS外的其他因素也会影响ASNase敏感性。